Overexpression of PIM 1, 2, and 3 kinases is frequently observed in many malignancies. Previously, we discovered a potent and selective pan-PIM kinase inhibitor, compound , currently in phase I clinical trials. In this work, we were interested in replacing the amino group on the cyclohexane ring in compound with a hydroxyl group. Structure-based drug design led to cellularly potent but metabolically unstable tetra-substituted cyclohexyl diols. Efforts on the reduction of Log D by introducing polar heterocycles improved metabolic stability. Incorporating fluorine to the tetra-substituted cyclohexyl diol moiety further reduced Log D, resulting in compound , a cellularly potent tetra-substituted cyclohexyl diol inhibitor with moderate metabolic stability and good permeability. We also describe the development of efficient and scalable synthetic routes toward synthetically challenging tetra-substituted cyclohexyl diol compounds. In particular, intermediate was identified as a versatile intermediate, enabling a large-scale synthesis of highly substituted cyclohexane derivatives.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.jmedchem.0c01279DOI Listing

Publication Analysis

Top Keywords

tetra-substituted cyclohexyl
20
cyclohexyl diol
16
pim kinases
8
cellularly potent
8
metabolic stability
8
tetra-substituted
5
cyclohexyl
5
synthesis structure-activity
4
structure-activity relationship
4
relationship tetra-substituted
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!